Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May;87(5):345-52.
doi: 10.1007/s00277-008-0449-0. Epub 2008 Feb 12.

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Aristoteles Giagounidis  1 , Pierre Fenaux, Ghulam J Mufti, Petra Muus, Uwe Platzbecker, Guillermo Sanz, Larry Cripe, Marie Von Lilienfeld-Toal, Richard A Wells
Affiliations
Review

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Aristoteles Giagounidis et al. Ann Hematol. 2008 May.

Abstract

Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q (del(5q)) cytogenetic abnormality. Although some patients with del(5q) have a relatively good prognosis, all del(5q) patients will become transfusion-dependent at some point during the course of their disease. The results of two clinical trials in more than 160 patients with MDS have demonstrated clear therapeutic benefits of lenalidomide, with >60% of patients achieving independence from transfusion during therapy, irrespective of age, prior therapy, sex, or disease-risk assessment. The recommendations presented in this review will aid the safe administration of lenalidomide for the treatment of patients with low-risk or intermediate-1-risk MDS and a del(5q) cytogenetic abnormality, and they will help physicians avoid unnecessary dose reduction or interruption, thus assuring the best efficacy for patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Recommendations for the management of a neutropenia and b thrombocytopenia. aNo consensus was reached, recommendation is based on the opinion of some of the panel members G-CSF granulocyte colony-stimulating factor
See this image and copyright information in PMC

References

    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. V.2.2008. Available from: http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed 4 December 2007 - PMC - PubMed
    1. None
    2. Hamblin TJ (2002) Epidemiology of the myelodysplastic syndromes. In: Bennett JM (ed) The myelodysplastic syndromes: pathobiology and clinical management. Marcel Dekker, New York, NY
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '9058730', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9058730/'}]}
    2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.leukres.2006.10.023', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.leukres.2006.10.023'}, {'type': 'PubMed', 'value': '17161457', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17161457/'}]}
    2. Olney HJ, Le Beau MM (2007) Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res 31:427–434 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1182/blood-2007-03-082404', 'is_inner': False, 'url': 'https://doi.org/10.1182/blood-2007-03-082404'}, {'type': 'PubMed', 'value': '17726160', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17726160/'}]}
    2. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2,124 patients. Blood 110:4385–4395 - PubMed

Publication types

MeSH terms